SCHEMBL5137292

SCHEMBL5137292

CCCn1c(CN(Cc2ccccc2)Cc2ccc3c(c2)OCCO3)cnc1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GBA1 P04062 1/20 0.39
CYP2D6 P10635 1/20 0.39
TSHR P16473 3/20 0.39
ALDH1A1 P00352 4/20 0.38
HPGD P15428 2/20 0.38
GAA P10253 2/20 0.38
HTT P42858 1/20 0.38
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GFER P55789 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
LMNA P02545 1/20 0.36
METAP2 P50579 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137683 0.94 C5AR1 (0.53) C5AR1SMN1; SMN2TDP1GBA1CYP2D6
SCHEMBL5137517 0.93 C5AR1 (0.50) C5AR1SMN1; SMN2TDP1GBA1CYP2D6
SCHEMBL1912837 0.92 C5AR1 (0.55) C5AR1SMN1; SMN2TDP1GBA1CYP2D6
SCHEMBL5134857 0.89 C5AR1 (0.60) C5AR1SMN1; SMN2TDP1TSHRALDH1A1
SCHEMBL5134695 0.88 C5AR1 (0.47) C5AR1SMN1; SMN2TDP1CYP2D6TSHR
SCHEMBL5135566 0.88 C5AR1 (0.57) C5AR1SMN1; SMN2TDP1TSHRALDH1A1
SCHEMBL650295 0.87 C5AR1 (0.48) C5AR1TSHRALDH1A1HPGDGAA
SCHEMBL1912862 0.86 C5AR1 (0.49) C5AR1SMN1; SMN2TDP1GBA1TSHR
SCHEMBL647999 0.86 C5AR1 (0.62) C5AR1SMN1; SMN2TDP1GBA1TSHR
SCHEMBL648765 0.86 C5AR1 (0.47) C5AR1SMN1; SMN2TDP1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7271270-B2 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2007-09-18 US disclosed
US-7271270-B2 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2007-09-18 US disclosed
US-20070027158-A1 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION 2007-02-01 US disclosed
US-20070027158-A1 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION 2007-02-01 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027158-A1 High affinity small molecule C5a receptor modulators C3AR1, C5AR1, C5AR2 C5AR1 2/4885SMN1; SMN2 4522/4885TDP1 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.